No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| GEHCGE HealthCare Technologies Inc. | 37.59B | 82.51 | 19.01 | 0.61% | 10.95% | 21.68% | 4.12% | 1.08 |
| ACONAclarion, Inc. | 4.22M | 4.00 | -0.00 | -39.36% | -108.68% | -58.67% | ||
| ONMDOneMedNet Corporation | 43.35M | 0.85 | -2.36 | -37.02% | -411.11% |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 17.16B | 17.59B | 18.34B | 19.55B | 19.67B |
| Revenue Growth % | - | 0.02% | 0.04% | 0.07% | 0.01% |
| Cost of Goods Sold | 10.4B | 10.41B | 11.16B | 11.63B | 11.47B |
| COGS % of Revenue | 0.61% | 0.59% | 0.61% | 0.59% | 0.58% |
| Gross Profit | 6.77B | 7.17B | 7.18B | 7.92B | 8.21B |
| Gross Margin % | 0.39% | 0.41% | 0.39% | 0.41% | 0.42% |
| Gross Profit Growth % | - | 0.06% | 0% | 0.1% | 0.04% |
| Operating Expenses | 4.05B | 4.38B | 4.66B | 5.49B | 5.58B |
| OpEx % of Revenue | 0.24% | 0.25% | 0.25% | 0.28% | 0.28% |
| Selling, General & Admin | 3.24B | 3.56B | 3.63B | 4.28B | 4.27B |
| SG&A % of Revenue | 0.19% | 0.2% | 0.2% | 0.22% | 0.22% |
| Research & Development | 810M | 816M | 1.03B | 1.21B | 1.31B |
| R&D % of Revenue | 0.05% | 0.05% | 0.06% | 0.06% | 0.07% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 2.72B | 2.79B | 2.52B | 2.44B | 2.63B |
| Operating Margin % | 0.16% | 0.16% | 0.14% | 0.12% | 0.13% |
| Operating Income Growth % | - | 0.03% | -0.1% | -0.03% | 0.08% |
| EBITDA | 3.35B | 3.42B | 3.15B | 3.04B | 3.21B |
| EBITDA Margin % | 0.2% | 0.19% | 0.17% | 0.16% | 0.16% |
| EBITDA Growth % | - | 0.02% | -0.08% | -0.03% | 0.05% |
| D&A (Non-Cash Add-back) | 630M | 625M | 633M | 610M | 580M |
| EBIT | 2.78B | 2.92B | 2.53B | 2.9B | 3.09B |
| Net Interest Income | -17M | -6M | -86M | -516M | -505M |
| Interest Income | 49M | 34M | 0 | 26M | 0 |
| Interest Expense | 66M | 40M | 86M | 542M | 505M |
| Other Income/Expense | -10M | 80M | -10M | -74M | -44M |
| Pretax Income | 2.71B | 2.88B | 2.51B | 2.36B | 2.58B |
| Pretax Margin % | 0.16% | 0.16% | 0.14% | 0.12% | 0.13% |
| Income Tax | 652M | 600M | 563M | 743M | 531M |
| Effective Tax Rate % | 5.11% | 0.78% | 0.76% | 0.66% | 0.77% |
| Net Income | 13.85B | 2.25B | 1.92B | 1.57B | 1.99B |
| Net Margin % | 0.81% | 0.13% | 0.1% | 0.08% | 0.1% |
| Net Income Growth % | - | -0.84% | -0.15% | -0.18% | 0.27% |
| Net Income (Continuing) | 2.06B | 2.27B | 1.95B | 1.62B | 2.05B |
| Discontinued Operations | 11.84B | 18M | 18M | -4M | 0 |
| Minority Interest | 247M | 241M | 235M | 177M | 206M |
| EPS (Diluted) | 4.41 | 4.90 | 4.22 | 3.02 | 4.34 |
| EPS Growth % | - | 0.11% | -0.14% | -0.28% | 0.44% |
| EPS (Basic) | 4.41 | 4.90 | 4.22 | 3.04 | 4.37 |
| Diluted Shares Outstanding | 454.71M | 454.71M | 453.93M | 458M | 459M |
| Basic Shares Outstanding | 454.71M | 454.71M | 453.93M | 455M | 456M |
| Dividend Payout Ratio | - | - | - | 0.03% | 0.03% |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 5.45B | 6.54B | 7.82B | 9.01B | 9.52B |
| Cash & Short-Term Investments | 1.01B | 556M | 1.45B | 2.5B | 2.89B |
| Cash Only | 1.01B | 556M | 1.45B | 2.5B | 2.89B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.66B | 3.79B | 3.99B | 4.32B | 4.38B |
| Days Sales Outstanding | 56.5 | 78.69 | 79.46 | 80.55 | 81.19 |
| Inventory | 1.59B | 1.95B | 2.15B | 1.96B | 1.94B |
| Days Inventory Outstanding | 55.96 | 68.22 | 70.47 | 61.51 | 61.72 |
| Other Current Assets | 190M | 250M | 226M | 231M | 311M |
| Total Non-Current Assets | 18.78B | 19.77B | 19.72B | 23.44B | 23.57B |
| Property, Plant & Equipment | 2.2B | 2.23B | 2.31B | 2.5B | 2.55B |
| Fixed Asset Turnover | 7.79x | 7.87x | 7.93x | 7.82x | 7.71x |
| Goodwill | 11.87B | 12.89B | 12.81B | 12.94B | 13.14B |
| Intangible Assets | 1.6B | 1.85B | 1.52B | 1.25B | 1.08B |
| Long-Term Investments | 709M | 665M | 663M | 733M | 804M |
| Other Non-Current Assets | 909M | 839M | 860M | 1.55B | 1.53B |
| Total Assets | 24.23B | 26.31B | 27.54B | 32.45B | 33.09B |
| Asset Turnover | 0.71x | 0.67x | 0.67x | 0.60x | 0.59x |
| Asset Growth % | - | 0.09% | 0.05% | 0.18% | 0.02% |
| Total Current Liabilities | 6.52B | 6.76B | 7.19B | 8.98B | 9.55B |
| Accounts Payable | 2.39B | 2.73B | 3.09B | 2.95B | 3.02B |
| Days Payables Outstanding | 83.8 | 95.68 | 101.04 | 92.49 | 96.19 |
| Short-Term Debt | 132M | 110M | 119M | 1.12B | 1.5B |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.27B | 1.17B | 1.23B | 1.48B | 1.45B |
| Current Ratio | 0.84x | 0.97x | 1.09x | 1.00x | 1.00x |
| Quick Ratio | 0.59x | 0.68x | 0.79x | 0.78x | 0.79x |
| Cash Conversion Cycle | 28.66 | 51.24 | 48.89 | 49.58 | 46.72 |
| Total Non-Current Liabilities | 2.73B | 2.65B | 10.76B | 16.16B | 14.88B |
| Long-Term Debt | 31M | 31M | 8.23B | 8.44B | 7.45B |
| Capital Lease Obligations | 305M | 296M | 282M | 311M | 310M |
| Deferred Tax Liabilities | 459M | 385M | 370M | 68M | 56M |
| Other Non-Current Liabilities | 1.37B | 1.31B | 1.24B | 6.64B | 6.38B |
| Total Liabilities | 9.25B | 9.41B | 17.95B | 25.14B | 24.44B |
| Total Debt | 468M | 437M | 8.63B | 9.86B | 9.38B |
| Net Debt | -539M | -119M | 7.19B | 7.36B | 6.49B |
| Debt / Equity | 0.03x | 0.03x | 0.90x | 1.35x | 1.08x |
| Debt / EBITDA | 0.14x | 0.13x | 2.74x | 3.24x | 2.93x |
| Net Debt / EBITDA | -0.16x | -0.03x | 2.28x | 2.42x | 2.02x |
| Interest Coverage | 41.21x | 69.88x | 29.33x | 4.49x | 5.20x |
| Total Equity | 14.97B | 16.9B | 9.59B | 7.31B | 8.65B |
| Equity Growth % | - | 0.13% | -0.43% | -0.24% | 0.18% |
| Book Value per Share | 32.93 | 37.16 | 21.13 | 15.96 | 18.85 |
| Total Shareholders' Equity | 14.73B | 16.66B | 9.36B | 7.13B | 8.45B |
| Common Stock | 0 | 0 | 0 | 5M | 5M |
| Retained Earnings | 0 | 0 | 0 | 1.33B | 3.26B |
| Treasury Stock | 0 | 0 | 0 | 0 | -25M |
| Accumulated OCI | 14.73B | 16.66B | 9.36B | -691M | -1.38B |
| Minority Interest | 247M | 241M | 235M | 177M | 206M |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 1.69B | 1.61B | 2.11B | 2.1B | 1.95B |
| Operating CF Margin % | 0.1% | 0.09% | 0.12% | 0.11% | 0.1% |
| Operating CF Growth % | - | -0.05% | 0.31% | -0.01% | -0.07% |
| Net Income | 2.06B | 2.27B | 1.95B | 1.62B | 2.05B |
| Depreciation & Amortization | 630M | 625M | 633M | 610M | 580M |
| Stock-Based Compensation | 0 | 76M | 67M | 114M | 125M |
| Deferred Taxes | 652M | 600M | 563M | 743M | 531M |
| Other Non-Cash Items | -1.6B | -599M | -806M | -1.01B | -1.28B |
| Working Capital Changes | -52M | -1.37B | -293M | 22M | -59M |
| Change in Receivables | -257M | -1.16B | -440M | -171M | -150M |
| Change in Inventory | 100M | -435M | -402M | 111M | -81M |
| Change in Payables | -113M | 263M | 481M | -13M | 126M |
| Cash from Investing | 19.99B | -1.76B | -398M | -558M | -914M |
| Capital Expenditures | -237M | -248M | -310M | -387M | -401M |
| CapEx % of Revenue | 0.01% | 0.01% | 0.02% | 0.02% | 0.02% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 20.3B | -32M | -29M | 24M | -160M |
| Cash from Financing | -21.54B | -263M | -822M | -478M | -573M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | -41M | -55M |
| Share Repurchases | - | - | - | - | - |
| Other Financing | -21.53B | -251M | -9.03B | -1.58B | -128M |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | 1.43B | 1.36B | 1.8B | 1.71B | 1.55B |
| FCF Margin % | 0.08% | 0.08% | 0.1% | 0.09% | 0.08% |
| FCF Growth % | - | -0.05% | 0.33% | -0.05% | -0.1% |
| FCF per Share | 3.14 | 2.99 | 3.97 | 3.74 | 3.38 |
| FCF Conversion (FCF/Net Income) | 0.12x | 0.72x | 1.10x | 1.34x | 0.98x |
| Interest Paid | 46M | 21M | 0 | 570M | 550M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 92.47% | 14.1% | 14.47% | 18.55% | 24.97% |
| Return on Invested Capital (ROIC) | 14.13% | 13.43% | 11.27% | 11.61% | 13.21% |
| Gross Margin | 39.43% | 40.8% | 39.14% | 40.52% | 41.71% |
| Net Margin | 80.67% | 12.78% | 10.45% | 8.02% | 10.13% |
| Debt / Equity | 0.03x | 0.03x | 0.90x | 1.35x | 1.08x |
| Interest Coverage | 41.21x | 69.88x | 29.33x | 4.49x | 5.20x |
| FCF Conversion | 0.12x | 0.72x | 1.10x | 1.34x | 0.98x |
| Revenue Growth | - | 2.45% | 4.3% | 6.6% | 0.61% |
| 2023 | 2024 | |
|---|---|---|
| Imaging | 10.58B | 8.86B |
| Imaging Growth | - | -16.31% |
| PCS | 3.14B | 3.13B |
| PCS Growth | - | -0.54% |
| PDx | 2.31B | 2.51B |
| PDx Growth | - | 8.76% |
| Ultrasound | 3.46B | - |
| Ultrasound Growth | - | - |
| 2023 | 2024 | |
|---|---|---|
| Other Countries | 8.76B | 8.92B |
| Other Countries Growth | - | 1.77% |
| UNITED STATES | 8.23B | 8.62B |
| UNITED STATES Growth | - | 4.73% |
| CHINA | 2.56B | 2.13B |
| CHINA Growth | - | -16.60% |
GE HealthCare Technologies Inc. (GEHC) has a price-to-earnings (P/E) ratio of 19.0x. This is roughly in line with market averages.
GE HealthCare Technologies Inc. (GEHC) reported $20.25B in revenue for fiscal year 2024. This represents a 18% increase from $17.16B in 2020.
GE HealthCare Technologies Inc. (GEHC) grew revenue by 0.6% over the past year. Growth has been modest.
Yes, GE HealthCare Technologies Inc. (GEHC) is profitable, generating $2.22B in net income for fiscal year 2024 (10.1% net margin).
Yes, GE HealthCare Technologies Inc. (GEHC) pays a dividend with a yield of 0.15%. This makes it attractive for income-focused investors.
GE HealthCare Technologies Inc. (GEHC) has a return on equity (ROE) of 25.0%. This is excellent, indicating efficient use of shareholder capital.
GE HealthCare Technologies Inc. (GEHC) generated $463.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.